Teva Launches Educational Hub to Boost Long-Acting Schizophrenia Treatment Adoption
Event summary
- Teva launched LongActingImpact.com on September 16, 2026, an educational website for healthcare providers focused on long-acting injectables (LAIs) for schizophrenia treatment.
- The resource aims to address low LAI adoption due to perceived patient resistance and operational complexities, with 67% of patients nonadherent to oral medications.
- Teva cites systemic hurdles and treatment conversation barriers as key obstacles to LAI utilization in schizophrenia care.
- The initiative aligns with Teva's broader strategy to expand its innovative medicines pipeline and improve schizophrenia treatment outcomes.
The big picture
Teva's launch of LongActingImpact.com reflects broader industry efforts to improve treatment adherence in schizophrenia care, where medication nonadherence remains a critical challenge. The initiative positions Teva as a leader in neuroscience, aiming to capitalize on the growing recognition of LAIs as a more effective alternative to oral medications. With 2.2 million diagnosed cases in the U.S., the potential market impact of improved adherence could be significant, both in terms of patient outcomes and healthcare cost reduction.
What we're watching
- Adoption Barriers
- Whether Teva's educational initiative can overcome systemic hurdles and operational complexities that currently limit LAI adoption.
- Treatment Outcomes
- How the increased use of LAIs may impact relapse rates and long-term patient outcomes in schizophrenia care.
- Market Positioning
- The pace at which Teva can differentiate itself in the competitive neuroscience space through targeted educational efforts.
Related topics